Sign in
Enrolling by invitationNo phase

A Wearable Temperature Patch to Watch for Cytokine Release Syndrome in Cancer Treatment

Tests a skin patch that tracks temperature in adults receiving cancer treatments.

Key facts

Who runs it
National Cancer Institute (NCI)
Where
Bethesda, United StatesSee the site
Trial code
Registry title
Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event
Status
Enrolling by invitation
People taking part
136 people, planned
Started
27 May 2026
Expected to end
18 Aug 2029
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • TempTraq
  • VitalTraq
Record updated
25 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cancer who are staying at the NIH Clinical Center for immunotherapy or cell therapy that can cause cytokine release syndrome (CRS). They wear a temperature patch to watch for fever.

Age
18 years and older
Sex
All sexes can join.
Disease stage
People in an active NIH treatment protocol with cellular therapy, cellular engagers, or other immunotherapy that carries a known or expected risk of grade >= 3 cytokine release syndrome (CRS). They must be receiving immunotherapy dose(s) and be admitted to the Clinical Center. Joining in the first week of treatment is preferred, but starting later is acceptable.
Earlier treatment
No prior solid organ or stem cell transplant while on active immunosuppression. No antibiotics for a documented active infection within 7 days before joining.

Main reasons for not taking part

  • Prior solid organ or stem cell transplant on active immunosuppression
  • Antibiotics for a documented active infection within 7 days before joining
  • A current syndrome with cyclic fevers
  • History of severe drug allergies, including DRESS
  • Alcohol or drug use disorder that would get in the way of the study, in the investigator's opinion

The registry criteria, word for word

Show all 10 criteriaShow less

Who cannot take part

  • Prior solid organ or stem cell transplantation on active immunosuppression
  • Regimen including antibiotics, for documented active infection within 7 days prior to study enrollment
  • Current syndrome associated with cyclic fevers
  • History of severe drug allergies, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
  • Known current alcohol use disorder or drug use disorder that, in the opinion of the investigator, would interfere with the participant s ability to comply with study procedures or safely participate in the study

Other criteria

  • INCLUSION CRITERIA:
  • Age >= 18 years
  • Participants must be enrolled in an active treatment protocol at NIH utilizing cellular therapy, cellular engagers, or other novel monotherapy or combination immunotherapy agents associated with a known or anticipated risk profile for grade >= 3 cytokine release syndrome (CRS) adverse effects
  • Participants must be receiving immunotherapy dose(s) and be admitted to the Clinical Center. Note: Enrollment during the first week of treatment on an active treatment protocol, when CRS risk is highest, is preferable, but starting later during their active treatment course is acceptable
  • Ability of the participant to understand and the willingness to sign a written informed consent document

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 120 years old?

Where in United States

  • National Institutes of Health Clinical CenterBethesda, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

Background:

Read full original descriptionShow less

Drugs or cell therapies to treat cancer can sometimes cause cytokine release syndrome (CRS). That is, the body makes too many cytokines after treatment. Cytokines are proteins that play a role in the immune system. CRS can cause fever, chills, fatigue, low blood pressure, or breathing problems. Researchers want to know if continuously monitoring a person s body temperature can help reduce the chance of getting serious CRS.

Objective:

To learn if an approved patch called TempTraq can detect fever before serious CRS develops.

Eligibility:

People aged 18 years and older with cancer who are staying at the NIH clinic for treatment with drugs or cell therapies.

Design:

Participants will receive TempTraq patches and a special NIH tablet. The TempTraq is a small patch applied to clean, dry skin under the arm. It continually monitors body temperature and sends the data to an application on the tablet.

Participants will wear the patch most of the time they are admitted to the hospital. They could wear it for up to 15 days. The patch monitoring does not replace regular temperature checks, all participants will still have have their regular temperature checks as part of their treatment plan.

Participants may also opt to use VitalTraq, another application on the tablet. They will hold the screen up to their face for about 1 minute. VitalTraq uses the camera in the tablet to measure blood pressure, heart rate, and breathing. They will do this once per day while they are in the clinic; they may do it more often if they have a fever or feel unwell.

Blood may be drawn for research.

Participants will be asked about their experience within 1 week after TempTraq is removed. Participants who choose to use the patch, complete its use, and return at a later date for another treatment or study, may be able to re-enroll to have the patch used again.

The 2 groups in the trial

  • Control Arm 2No study treatment, for comparison

    Use of non-readable CTM devices, TempTraq without actionable alerts, and optional use of black-boxed VitalTraq

  • Intervention Arm 1Treatment being tested

    Use of non-readable CTM devices, TempTraq with actionable alerts, and optional use of black-boxed VitalTraq

    Treatment: TempTraq and VitalTraq

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event
Plain-language title
A Wearable Temperature Patch to Watch for Cytokine Release Syndrome in Cancer TreatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Fit questions
Built from NCT07499128, who can take part
Record updated
25 June 2026